Health Canada's approval of Taltz™ (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis
KAIT-TV,
SOURCE Eli Lilly Canada Inc. TORONTO More than 500,000 Canadians are living with psoriasis.2 Plaque psoriasis, the most common…